Citius Pharmaceuticals (CTXR) Maxim Group’s 2024 Healthcare Virtual Summit summary

Strategic developments and business structure

• Completed a spin-out of an approved oncology product, Lymphir, into Citius Oncology, with a planned launch in January 2025.

• Citius Pharmaceuticals retains 92% ownership of Citius Oncology, with plans to distribute Oncology shares to current shareholders and consolidate financial results.

• Spin-out structure aims to minimize dilution for the parent company while raising funds for the Lymphir launch.

• Citius Oncology will transition from pre-revenue to revenue-generating status, with profitability anticipated by end of 2025.

Product pipeline and clinical progress

• Lymphir, approved for cutaneous T-cell lymphoma, targets a $300–$400 million market, competing with Adcetris and Poteligeo.

• Mino-Lok, for catheter-related bloodstream infections, showed highly significant phase III results (p=0.0006) and is preparing for FDA discussions in late November.

• Halo-Lido, targeting stage 2 and 3 hemorrhoids, is preparing for FDA protocol discussions and may be out-licensed or sold after further data.

Market dynamics and competitive positioning

• Lymphir is expected to expand the CTCL market, as new entries have historically been additive rather than competitive.

• Lymphir’s unique mechanism of action may enhance efficacy when combined with Keytruda, with investigator-initiated trials ongoing.

• Mino-Lok is positioned as a cost-saving hospital treatment, priced below catheter replacement procedures ($4,000–$5,000 vs. $10,000–$12,000).

• Mino-Lok treats infections, while DefenCath is for prevention in dialysis; the two address different market segments.